Adrenomedullin (ADM) inhibits endothelial insulin signaling, contributing to obesity-associated insulin resistance, according ...

Researchers investigate the underlying mechanisms of endothelial insulin resistance involved in obesity-associated diabetes.

If insulin can’t get out of blood vessels, it can’t act in its target tissues. “Endothelial cells are full of insulin ...

Adrenomedullin disrupts insulin signaling in blood vessels, leading to systemic insulin resistance in obesity-associated type 2 diabetes.

Scientists have discovered that the peptide hormone adrenomedullin plays a pivotal role in obesity-related type 2 diabetes, ...

The hormone adrenomedullin disrupts insulin signaling in blood vessel cells, contributing to systemic insulin resistance in obesity-associated type 2 diabetes, according to a new study.

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

The hormone adrenomedullin disrupts insulin signaling in blood vessel cells, contributing to systemic insulin resistance in obesity-associated type 2 ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

REDWOOD CITY, Calif. - Rezolute , Inc. (NASDAQ:RZLT), a biopharmaceutical company with a market capitalization of $303.62 million and impressive recent momentum (up 13.91% in the past week), announced ...

We report that S1P-related gene expression in MG is modulated by microglia and inhibition of S1P receptors or S1P synthesis partially rescues the loss of MGPC formation in damaged retinas missing ...